Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... with an average of 25.5 days to return the kit; This supports mt-sDNA as an effective ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC ... with an average of 25.5 days to return the kit; This supports mt-sDNA as an ...

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... 1.2 million patients including a record number with Cologuard and Etty DX. Growing total revenue 13% ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...